Jefferies Initiates Coverage On Acelyrin with Buy Rating, Announces Price Target of $31
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Akash Tewari initiates coverage on Acelyrin (NASDAQ:SLRN) with a Buy rating and announces a price target of $31.
May 30, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Akash Tewari initiates coverage on Acelyrin with a Buy rating and a price target of $31.
Jefferies initiating coverage on Acelyrin with a Buy rating and a price target of $31 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100